First Tracks Earnings & Forecasts - Benzinga

First Tracks Biotherapeutics Inc

TRAXNASDAQ

Trade with Public

Trade with Public

$45.72

0.340.75%

Últ. Act.: Oct 28, 4:46 PM

Panorámica general NoticiasPrevisión de beneficiosEventos Precios objetivo Finanzas Sentimiento Propiedad Comparar Informe de acciones

First Tracks Earnings & Forecasts

First Tracks (TRAX) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Revenue (Billions)

First Tracks Guidance

Recent Earnings Results

Metric	Q2 '26
Earnings Per Share (Non-GAAP)
Estimate	—
Actual	$-0.95
Surprise	—
Revenue
Estimate	—
Actual	$0
Surprise	—

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.89	$-0.84	$-0.92	$-0.94
Revenue
Consensus	—	—	—	—

Earnings & Guidance News

Stock Market Today: S&P 500, Dow Jones Futures Gain Even as Iran Flags 'Inadequate' US Response to Peace Terms — SMP, QMCO, SVRN in Focus

U.S. stock futures were mixed on Monday, as the Dow Jones and S&P 500 indices rose, while the Nasdaq 100 index fell.

Rishabh Mishra

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.

Avi Kapoor

PRO
First Tracks Q2 EPS $(0.95) Up From $(1.47) YoY

First Tracks (NASDAQ:TRAX) reported quarterly losses of $(0.95) per share. This is a 35.37 percent increase over losses of $(1.47) per share from the same period last year.

Benzinga Newsdesk